← 返回

肿瘤相关巨噬细胞在癌症治疗中的前景

英文原题:The promising role of tumor-associated macrophages in the treatment of cancer.

查看英文原题

The promising role of tumor-associated macrophages in the treatment of cancer.

PubMed 2024/01/03(内容时间) Drug Resist Updat Q1 · IF 22(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

巨噬细胞是免疫系统的重要组成部分。成熟的巨噬细胞可被招募至肿瘤微环境,影响肿瘤细胞增殖、侵袭和转移、细胞外基质重塑、免疫抑制以及化疗耐药。经典激活的I型巨噬细胞(M1)表现出显著的肿瘤杀伤和吞噬作用。因此,利用巨噬细胞进行过继细胞治疗已引起关注,并成为癌症治疗最有效的策略之一。通过细胞因子和/或趋化因子,巨噬细胞可以抑制髓系细胞招募,并激活抗肿瘤和免疫杀伤功能。应用巨噬细胞进行抗肿瘤递送是癌症治疗最有前景的方法之一。本文综述了巨噬细胞在肿瘤发展和耐药中的作用,以及靶向巨噬细胞以克服耐药和增强癌症治疗的可能临床应用及其挑战。

展开英文摘要原文

Macrophages are important components of the immune system. Mature macrophages can be recruited to tumor microenvironment that affect tumor cell proliferation, invasion and metastasis, extracellular matrix remodeling, immune suppression, as well as chemotherapy resistance. Classically activated type I macrophages (M1) exhibited marked tumor killing and phagocytosis.

Therefore, using macrophages for adoptive cell therapy has attracted attention and become one of the most effective strategies for cancer treatment. Through cytokines and/or chemokines, macrophage can inhibit myeloid cells recruitment, and activate anti-tumor and immune killing functions.

Applying macrophages for anti-tumor delivery is one of the most promising approaches for cancer therapy. This review article introduces the role of macrophages in tumor development and drug resistance, and the possible clinical application of targeting macrophages for overcoming drug resistance and enhancing cancer therapeutics, as well as its challenges.

论文信息

作者
Wang H、Wang X、Zhang X、Xu W
第一作者单位
NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, PR China; Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin Medical University, PR China; Department of Surgical Oncology, Harbin Medical University Cancer Hospital, PR China. Electronic address: wanghongbin@hrbmu.edu.cn.China
通讯作者单位
NHC and CAMS Key Laboratory of Molecular Probe and Targeted Theranostics, Harbin Medical University, PR China; Heilongjiang Key Laboratory of Scientific Research in Urology, Harbin Medical University, PR China; Department of Urology, Harbin Medical University Cancer Hospital, PR China. Electronic address: xuwanhai@hrbmu.edu.cn.China
文献类型
综述
期刊
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy2024 Mar
原文标识
PubMed 38198845 · DOI 10.1016/j.drup.2023.101041